The PSMA-PET imaging agent will be used for patients who have suspected metastasis and those with suspected cancer recurrence.

The PSMA-PET imaging agent will be used for patients who have suspected metastasis and those with suspected cancer recurrence.

A new at-home saliva test could help identify men with a high risk of prostate cancer more accurately than blood tests, ...

TLX007-CDx was approved by the FDA for PSMA-PET scanning in adult male patients with prostate cancer with suspected ...

Telix Pharmaceuticals reported that the U.S. Food and Drug Administration approved its agent indicated for prostate cancer ...

The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 ...

Telix Pharmaceuticals' said its new drug application in the U.S. for an imaging agent received regulatory approval. The Melbrourne, Australia-based biopharmaceutical company said Friday that the Food ...

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food ...

Symptoms of prostate cancer may include needing to urinate more frequently; having to rush to the toilet; straining to ...

Telix Pharmaceuticals Limited today announces that the United States Food and Drug Administration has approved its New Drug Application for Gozellix® gozetotide injection), Telix's next-generation ...

A groundbreaking treatment for prostate cancer now available in Virginia aims to improve patient outcomes while minimizing side effects associated with traditional surgeries and radiation therapies.

The ASX 200 healthcare stock received another FDA approval for its cancer detection product. The post Up 113% in a year, ...